Skip to main content
Enclose phrases in quotes. Use a + to require a term in results and - to exclude terms.
Example: +water -Europe
Main navigation - Mobile
10. Astellas, Amgen—$125M combined
10. Astellas, Amgen—$125 million combined
Amgen sales slide as copies dig into Sensipar, Neulasta
Tuesday, July 30, 2019
Amgen is working to grow sales for new meds, but in the second quarter, costly losses of exclusivity for Sensipar and Neulasta hurt the drugmaker.
DOJ: Astellas, Amgen fork over $125M to settle kickback probes
Thursday, April 25, 2019
Astellas and Amgen agreed to pay nearly $125 million to settle Justice Department allegations that they used charity contributions as kickbacks.
Amgen, Teva strike Sensipar patent deal after brief launch
Thursday, January 3, 2019
After Teva launched its generic Sensipar for a matter of days, Amgen and Teva now have a patent deal delaying the generic drugmaker's rollout until mid-2021.
Mylan biosim ready to challenge Amgen blockbuster Neulasta
Tuesday, June 5, 2018
Amgen's $3.9 billion Neulasta, one of the biggest drug targets for biosim developers, is finally slated to face competition after a 2015 patent loss.
Patent fights jump in 2017, led by Eli Lilly, Pfizer, Sanofi and more
Friday, May 4, 2018
Top drugmakers made more trips to the courthouse last year, aiming to blockade big-selling drugs against generic competitors.
Amgen, Sandoz trial over Enbrel patents delayed, filings suggest
Monday, April 2, 2018
Sandoz may have to wait a little longer for a clear shot at launching a biosimilar to Amgen's anti-inflammatory blockbuster Enbrel.
Amgen’s Sensipar is yet another example of the complicated process of anticipating generic launches. The drug's primary patent expired March 8, but it also boasts a 2026 formulation patent that it’s using to try to defend its blockbuster.
Amgen faces one-two blow from Repatha, Sensipar competition
Tuesday, March 13, 2018
Amgen faces generic competition to its thyroid medication, Sensipar, and the potential to lose share in the PCSK9 cholesterol drug market. Now what?